ETF Portfolio Partners’s Sarepta Therapeutics SRPT Stock Holding History

ETF Portfolio Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,786	Closed	-$231K	–	59
2024 Q1	$231K	Buy	+1,786	New	+$219K	0.07%	52
2023 Q4	–	Sell	-1,786	Closed	-$217K	–	49
2023 Q3	$217K	Hold	1,786	–	–	0.08%	44
2023 Q2	$205K	Hold	1,786	–	–	0.07%	46
2023 Q1	$246K	Buy	1,786 +240	+16%	+$31.1K	0.09%	46
2022 Q4	$200K	Buy	+1,546	New	+$179K	0.08%	48
2021 Q1	–	Sell	-4,328	Closed	-$738K	–	52
2020 Q4	$738K	Hold	4,328	–	–	0.34%	25
2020 Q3	$608K	Hold	4,328	–	–	0.32%	27
2020 Q2	$694K	Buy	4,328 +1,193	+38%	+$162K	0.38%	25
2020 Q1	$307K	Buy	3,135 +500	+19%	+$57.2K	0.2%	29
2019 Q4	$340K	Buy	+2,635	New	+$266K	0.18%	29
2019 Q3	–	Sell	-2,635	Closed	-$400K	–	33
2019 Q2	$400K	Hold	2,635	–	–	0.21%	29
2019 Q1	$314K	Hold	2,635	–	–	0.19%	29
2018 Q4	$288K	Hold	2,635	–	–	0.19%	29
2018 Q3	$426K	Hold	2,635	–	–	0.26%	25
2018 Q2	$348K	Buy	+2,635	New	+$248K	0.22%	20

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ETF Portfolio Partners's SRPT Position: Q2 2024 in Review

ETF Portfolio Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 1,786 shares — an estimated $231K sold.

ETF Portfolio Partners first reported a position in SRPT in Q2 2018 and held it in 15 quarters. The position peaked at $738K in Q4 2020. 484 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

ETF Portfolio Partners reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
ETF Portfolio Partners sold 1,786 Sarepta Therapeutics shares in Q2 2024, an estimated $231K.
ETF Portfolio Partners first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 15 quarters.
ETF Portfolio Partners's Sarepta Therapeutics position peaked at $738K in Q4 2020.
484 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on ETF Portfolio Partners's 13F filing for Q2 2024, filed 15 Jul 2024.